Icon

Acanya - (2.5%; EQ 1.2% BASE; Gel, Topical)

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE Dow Pharma
2.5%; EQ 1.2% BASE; Gel, Topical
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
None
Less Than 5
Less Than 5
Used on the skin (topical) to treat acne vulgaris in people 12 years and older.
Yes
****(*******) ** *** ***** ** **** **** ** **** ******* ‘*** (****** *, ****), ‘*** (**** *, ****) *** *** ************ *********. ***** **** ***** **** ** ** ******* ‘*** (****** *, ****), ‘*** (**** *, ****). ** ****** **** **** **** ******* ** *** ****. ****** *** ******* ** *** ******** ** *** ****** ******* *** ********* ******* * ********** ********* ** *** ***** ** ***** **** (*******) *** ****** ** **** *, ****. * ******* ********** *** ******* **** **** ** ****. ******** ****** **** ** **** *** ** ******* *** ****** ***** **** (*******). ******* ** **** ******** *** ******** ******. ******* ******* **** *** **** *** ******** *** ******* ** ***.
Acanya Patent 1 Patent 2 Patent 3 Patent 4 Patent 5
******* ******* ******* ******* ******* *******
******* ******* ******* ******* ******* *******
*** (****) ******* ******* ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
******* *** \ *** **** *, **** ******* ******** ******** ** *** **, ****
******* ** \ ** *** **, **** ******* ******** ******** ** **** **, ****
*** (****) ** \ ** *** **, **** ******* ******** ******** ** *** **, ****
  1. *** *, **** : ******* ***** **** ** **** ******* ‘*** (****** *, ****), ‘*** (**** *, ****) *** *** ************ *********.
  2. *** **, **** : *** ***** * **** ******* ******* ** ****** ‘*** (****** *, ****)
  3. *** **, **** : **** ******** *** ***** *** **** ** *** ****** **** ******* ‘*** (****** *, ****), ‘*** (**** *, ****)
  4. *** **, **** : *** *** ******* ****** ***** * **** ******* **** ** ******** ***** ** **
  5. *** *, **** : ******* *** ******* ******* * ********** ********* ** *** ***** ** ***** ******* *** ****** *** ******* ** **** *, ****.
  6. **** **, **** : ********** ********* **** *******, ********* ** *** ***** ** ***** ******* *** ****** *** ******* ** ******** **, ****
  7. **** **, **** : * ****** *** **** ******* * **********, ********* ** *** ***** ** ***** **** *** ****** *** ******* ** ******** **, ****
  8. *** *, **** : *** *** ******* ****** ***** * **** ******* ****** ** ******* ‘*** (****** *, ****), ‘*** (**** *, ****)
  9. *** **, **** : ********** ********* **** ******, ********* ** *** ***** ** ***** ****** *** ****** *** ******* ** ******** **, ****
  10. *** **, **** : **** ******** ******* ****** ** **

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.